1. Yusuf S, Hawken S, Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet2004;364:937–52.
2.
2. Geiss LS, Herman WH, Smith PJ. et al. Diabetes in America, 2nd edition. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1995.
3.
3. Nathan DM, Buse JB, Davidson MB. et al. Management of hyper-glycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2006;29:1963–72.
4.
4. United Kingdom Prospective Diabetes Study.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837–52.
5.
5. United Kingdom Prospective Diabetes Study.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998;317:703–13.
6.
6. Turner RC, Millns H, Neil HAW. et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. UKPDS 23. BMJ1998;316:823–8.
7.
7. Baigent C, Keech A, Kearney PM. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366:1267–78.
8.
8. Nissen SE, Nicholls SJ, Sipahi I. et al. Effect of very high intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA2006;295:1556–65.
9.
9. Nissen SE, Tuzcu EM, Schoenhagen P. et al. for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering treatment on progression of coronary atherosclerosis: a randomised controlled trial. JAMA2004;291:1071–80.
10.
10. Nissen SE, Tuzcu EM, Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study, a randomised controlled trial. JAMA2004;292:2217–25.
11.
11. Costa J, Borges M, David C, Vaz Carneiro A.Efficacy of lipid-lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ2006;332:1115–24.
12.
12. Scandinavian Simvastatin Survival Study Group.Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet1995;345:1274–5.
13.
13. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998;339:1349–57.
14.
14. Pfeffer MA, Sacks FM, Moye LA. et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. J Am Coll Cardiol1999;33:125–30.
15.
15. Shepherd J, Cobbe SM, Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med1995;333:1301–07.
16.
16. Downs CR, Clearfield M, Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA1998;279:1615–22.
17.
17. Frick MH, Elo O, Haapa K. et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med1987;317:1237–45.
18.
18. Goldbourt U, Behar S, Reicher-Reiss H et al. Rationale and design of a secondary prevention trial of increasing high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention study). Am J Cardiol1993;71:909–15.
19.
19. Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. The Veterans Administration High-density cholesterol Intervention Trial study group. N Engl J Med1999;341:410–18.
20.
20. Keech A, Simes RJ, Barter P. et al. FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes (the FIELD study): randomised controlled trial. Lancet2005;366:1849–61.
